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Introduction
The use of etanercept, a tumor necrosis factor (TNF)
inhibitor, has revolutionized the treatment of juvenile idio-
pathic arthritis (JIA). TNF is a key cytokine implicated in
the pathogenesis of inflammatory arthritis and etanercept,
which is a soluble TNF receptor fusion protein, binds and
inactivates TNF-a and lymphotoxin-A.
Objectives
The aim of this study was to profile serum levels of TNF-a
in a large cohort of adolescent patients with JIA.
Methods
Serum TNF-a was measured in samples derived from 200
adolescent and young adult patients with JIA attending
the adolescent and young adult rheumatology clinic at
University College London Hospital using a commercial
enzyme linked immunosorbent assay (ELISA) kit
(eBioscience). Samples were tested in duplicate. Median
age at sampling and median disease duration were 18
years and 8 years 9 months, respectively. Male:female ratio
was 1:1.2. Equal numbers of patients with polyarticular
(n=64) and enthesitis related arthritis (ERA, n=64) were
tested in addition to 48 with oligoarticular, 16 systemic
onset, and 8 psoriatic arthritis. Erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP) measurements
were also collected. Furthermore, an L929 cell viability
bioassay was used to determine if the addition of
etanercept abrogates the cytotoxic effects of TNF-a in
L929 cells.
Results
Surprisingly, TNF-a serum levels were shown to be
markedly elevated in patients on etanercept (median
TNF-a on etanercept= 134.2pg/ml, IQR [49.4-207.1],
median not on etanercept = 4.2pg/ml, IQR [1.4-11.0],
p<0.0001). TNF-a levels were also higher in patients
on etanercept compared to those on other biologics
(adalimumab, infliximab, abatacept, or tocilizumab,
median= 4.4pg/ml, IQR [1.8-9.1]) or disease modifying
anti-rheumatic drugs alone (median = 4.2 pg/ml, IQR
[1.1-12.9]), p<0.0001. In addition, ESR and CRP levels
had a negative correlation with high TNF-a levels in
patients on etanercept (p=0.0018 and p=0.0034 respec-
tively). Etanercept was included at its therapeutic
serum concentration (2.4ug/ml) to ensure there was no
cross reactivity with the assay. Finally, we showed that
the addition to TNF-a to human serum leads to
cytotoxicity in a TNF-a sensitive cell line, while adding
etanercept at its therapeutic concentration along with
TNF-a significantly reduces cell death (p = 0.0277).
Conclusion
Patients treated with etanercept have higher levels of
TNF-a. As the majority of patients with elevated TNF-a
on etanercept were in remission, it is likely that this cir-
culating TNF is biologically inactive. This is supported by
our in vitro experiments in which the cytotoxic effect of
TNF-a was abrogated upon addition of etanercept. Our
hypothesis is that etanercept prolongs the half-life of
circulating TNF-a. Further studies are needed to confirm
these findings and dissect the mechanisms involved. As
the association between high TNF-a and etanercept
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treatment is so strong, we hypothesise that it may be
possible to measure TNF-a levels as a surrogate marker
of adherence to this drug in this cohort of patients where
adherence to medication can be a significant problem.
This is a hypothesis that warrants further investigation.
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